## Abstract ## Background and Objective We present our clinical experiences of two recently introduced vaporization laser systems: the GreenLight High Performance System (HPS) laser (532 nm, 120 W) and the Diolas LFD diode laser (980 nm, 200 W). ## Materials and Methods Two laser systems were ev
Single center experience with GreenLight laser vaporization of the prostate – A review
✍ Scribed by Malte Rieken; Alexander Bachmann
- Publisher
- Elsevier Science
- Year
- 2011
- Tongue
- English
- Weight
- 107 KB
- Volume
- 26
- Category
- Article
- ISSN
- 1615-1615
No coin nor oath required. For personal study only.
✦ Synopsis
Introduction: Laser vaporization of the prostate with the GreenLight laser has emerged as a treatment alternative to TURP. Materials and methods: An analysis of the published data of our center was performed to assess the safety, the efficacy and the long-term results of the technique.
Results: GreenLight laser vaporization of the prostate is characterized by an outstanding intraoperative safety, regardless of oral anticoagulation or prostate size. The early and midterm functional outcome are comparable to TURP, however the data lack randomization.
Conclusions: Laser vaporization of the prostate with the GreenLight laser is a safe and effective treatment modality for patients with bladder outlet obstruction due to benign prostate enlargement and has gained wide acceptance in the urological community.
📜 SIMILAR VOLUMES
## Abstract ## Background and Objective Anatomic, tissue ablation and coagulation, and histopathologic outcomes of the 150‐W 980‐nm diode laser selective light vaporization (SLV™) of the prostate in the first survival study of living canines were analyzed. ## Study Design/Materials and Methods T
Liver transplantation may occasionally be indicated in patients with unique clinical scenarios. Little is known regarding the outcomes of patients who have had a pancreatic resection prior to, in combination with, or after liver transplantation. A retrospective review of all patients undergoing live
## Abstract ## BACKGROUND. Bortezomib is active in heavily pretreated multiple myeloma patients; the dose‐limiting toxicity is peripheral neuropathy (PN). ## METHODS. The authors retrospectively reviewed the incidence, severity, and risk factors for PN in 78 patients who received bortezomib. The
## Abstract Antibody‐mediated rejection (AMR) has been recognized as a major cause of renal allograft loss. Protocols using plasma exchange (PE) to reverse rejection have mixed results. **Methods:** A retrospective chart review was performed to determine the clinical response to PE inpatients with